Skip to content

NEOGEN DEVELOPMENTS

Absorbed by Neogen NV KBO/BCE: BE 0808.426.110 subsidiary of Alter Pharma Group NV
NEOGEN DEVELOPMENTS
Follow Report

Overview

Lifetime

10 annual accounts with figures on one time axis
peak €9.4m (2013)
-not published
lowest -€76,722 (2019)
-€76,722▼ €56,976
peak €369,248 (2018)
€292,526▼ 20.8%
€417,848▼ 25.3%
Board4 names since 2020
- 
Owners3 names in the annual accounts
100%NEOGEN and 1 other
Documentsfilings and deeds
14-07-202017 days before the deadline
2019abbreviated format
Loss of €76,722Equity from €369,248 to €292,526Debts from €559,499 to €417,848

Key points

from the 2019 annual accounts, the last ones filed

Result

-€76,722 ▼ 289%
-€19,7002018-€76,7002019

The result fell in 2019 from -€19,745 to -€76,722.

Liquidity

1.70 was 3.59 in 2018

Short-term debts rose from €258,824 to €417,848.

Filings

10 annual accounts 11 filings, 2 late
AprilJune31 JulyOctober20102015

The 2011 accounts came latest: 28 days after the end of the period.

No score

Board and ownership

last known board
AP
Alter Pharma NV
Director, until 2020
GI
GRNR Invest BV
Director, until 2020
HO
HANDS-ON FINANCE SOLUTIONS
Director, last mentioned in 2020
JM
Jacobsen Management
Director, last mentioned in 2020
Board & ownership

Recent changes

Merger: absorbed by Neogen General meeting of 30-06-2020 · Gazette deed
Merger proposal: to be absorbed by Neogen NV Permanent representative: Julie Delforge · Neogen NV holds all the shares · Alter Pharma NV holds all the shares · Gazette deed
2 directors appointed, 2 resignations Resignations: GRNR Invest BV and Alter Pharma NV · Permanent representatives: Thomas Jacobsen, Pieter Van Rompay and Ivo Peeters · Appointments: Jacobsen Management BV and HFS BV · General meeting of 12-02-2020 · Gazette deed
Incorporation 12 publications in the Belgian Official Gazette, the last on 23-07-2020 · Gazette deed
All 23 events

Official details

Source: KBO
Status
Absorbed by Neogen NVmerger by absorption, July 2020
Activity
“Alle roerende,onroerende,financiële,industriële,commerciële of burgerrechtelijke verrichtingen binnen de perken van haar maatschappelijk doel,zowel in België…” (deed in Dutch)From the articles, 2 activitiesNo NACE code in the KBO yet
Financial year end
31 December
Peppol
Not found in the Peppol Directory
Company details

Annual accounts 2019

-€16,779
€76,722▲ 289%
€292,526▼ 20.8%
€710,375▼ 23.5%
Filing
Filed on 14-07-2020
Financials

Insights on NEOGEN DEVELOPMENTS

Absorbed by Neogen NV in July 2020. The last annual accounts are for financial year 2019.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette.

Financials

Annual accounts 2019

abbreviated format, filed on 14-07-2020, 17 days before the deadline
-€16,779
-€66,953
▼ €43,436
-
-
41.2%
▲ 1.4 percentage points
1.70
▼ 1.89

Money flows

no detail for 2019

Balance sheet

balance sheet total €710,375 on 31-12-2019
What the company ownsHow it is paid for

in euro

in euro

Filed annual accounts

as filed with the National Bank, click a year to choose it
Line Trend2019201820172016201520142013201220112010
Balance sheet: assets
20/58 710,375928,7472.8m3.1m1.9m4.2m3.6m3.3m1.3m51,080
21/28 -------290581-
22/27 -------290581-
23 -------290581-
29/58 710,375928,7472.8m3.1m1.9m4.2m3.6m3.3m1.3m51,080
3 --417,532296,402176,099423,963583,553604,027--
30/36 --417,532296,402176,099423,963583,553604,027--
30/31 --417,532235,166103,001271,448212,122---
34 ---61,23673,098152,515371,431---
40/41 652,387860,5221.8m2.7m1.6m3.4m2.5m2.6m1.3m39,580
40 121,547278,834987,1511.0m884,8931.8m1.0m1.8m76,426-
41 530,840581,688767,7411.7m745,9491.6m1.5m756,8871.2m39,580
54/58 57,98868,225641,34064,92050,36439,808146,246158,17975611,500
490/1 -----336,000436,000---
Balance sheet: equity and liabilities
10/49 710,375928,7472.8m3.1m1.9m4.2m3.6m3.3m1.3m51,080
10/15 292,526369,248309,933225,566181,102117,32547,02074,04252,59049,862
10/11 61,50061,50061,50061,50061,50061,50061,50061,50061,50061,500
100 61,50061,50061,50061,50061,50061,50061,50061,50061,50061,500
13 6,1506,1506,1506,1506,1506,1506,1506,150--
130 6,1506,1506,1506,1506,1506,1506,1506,150--
14 224,876301,598242,283157,916113,45249,675-20,6306,392-8,910-11,638
17/49 417,848559,4992.5m2.8m1.7m4.1m3.6m3.3m1.2m1,218
17 -300,399---25,712176,359287,144459,787-
170/4 -300,399---25,712176,359287,144459,787-
173 -300,399---25,712176,359---
42/48 417,848258,8242.5m2.8m1.7m4.1m3.4m2.6m752,5711,218
42 ----25,712150,647144,611172,643133,255-
43 --300,000300,000300,000300,000300,000300,000300,000-
430/8 --300,000300,000300,000300,000300,000300,000300,000-
44 96,444169,4362.2m2.5m1.2m3.6m3.0m2.1m319,3161,218
440/4 96,444169,4362.2m2.5m1.2m3.6m3.0m2.1m319,3161,218
45 -30,77841,98139,00070,00037,000-47,784--
450/3 -30,77841,98139,00070,00037,000-47,784--
47/48 321,40458,611--105,124-----
492/3 -276-----386,461--
Income statement
70/76A -227,0804.2m5.0m3.3m7.6m9.4m---
70 -108,2014.1m4.9m3.3m7.6m9.4m---
9900 -16,779------38,23222,256-10,896
60/66A -250,5974.1m4.9m2.9m7.5m9.4m---
60 --2.1m2.5m1.6m4.0m6.6m---
600/8 --2.2m2.6m1.4m3.9m6.5m---
609 ---121,130-120,303247,864133,40620,474---
61 -253,1972.0m2.3m1.2m3.4m2.7m---
630 ------290290291-
631/4 49,306-3,468-39,122-5,7761,698138,80725,000---
640/8 86886892,207127,77088,27313,528114,486452366742
9901 -66,953-23,517106,803116,661387,252129,33034537,49021,599-11,638
75/76B 2,0816,27525,24513,02268,932102,2847,23723,43012,965-
75 2,0816,27525,24513,02268,932102,2847,23723,43012,965-
751 -6,27224,5573,99968,603102,0166,553---
752/9 -36889,023329269684---
65/66B 11,8508,7258,53815,836359,407124,30934,47937,19731,818-
65 11,8508,7258,53815,836359,407124,30934,47937,19731,818-
650 -8,0855,8686,48111,49216,62823,440---
651 ----336,000100,000----
652/9 -6402,6709,35511,9157,68111,038---
9903 -76,722-25,968123,511113,84796,777107,305-26,89723,7242,746-11,638
67/77 --6,22239,14369,38333,00037,0001242,27218-
670/3 -30,77841,98169,38333,00037,000124---
77 -37,0002,838-------
9904 -76,722-19,74584,36744,46463,77770,305-27,02221,4522,728-11,638
9905 -76,722-19,74584,36744,46463,77770,305-27,02221,4522,728-11,638
Appropriation of the result
9906 224,876301,598242,283157,916113,45249,675-20,63012,542-8,910-11,638
691/2 -------6,150--
6920 -------6,150--
Document PDFPDFPDFPDFPDFPDFPDFPDFPDFPDF

Source: Annual accounts 2019 (PDF), filed on 14-07-2020.

Download as CSV

Filings

each dot is a set of accounts, on the day it reached the National Bank
Financial year Type Filed Reference Document
31-12-2019 abbreviated format 14-07-2020 2020-30400482 PDF
31-12-2018 full format 09-07-2019 2019-31200391 PDF
31-03-2018 full format 26-10-2018 2018-70400420 PDF
31-03-2017 full format 08-11-2017 2017-69500061 PDF
31-03-2016 full format 25-10-2016 2016-66200366 PDF
31-03-2015 full format 19-10-2015 2015-65300042 PDF
31-03-2014 full format 28-10-2014 2014-65800187 PDF
31-03-2013 full format 31-10-2013 2013-65000601 PDF
31-03-2012 abbreviated format 25-10-2012 2012-61900563 PDF
31-03-2011 abbreviated format 28-11-2011 2011-62100169 PDF
31-03-2010 abbreviated format 27-09-2010 2010-55300398 PDF

Key figures and ratios

per financial year, computed from the annual accounts
Line Trend2019201820172016201520142013201220112010
------63537,78121,890-
-------26,73121,7423,019-
------0-0871-
-10,237-573,115576,42014,55610,556-106,438-11,933157,423-10,744-
292,526669,922309,933225,566181,102143,037223,379747,357511,79649,862
--21.7%2.6%2.4%11.8%1.7%0.0%---
41.2%39.8%11.0%7.4%9.8%2.8%1.3%2.2%4.2%97.6%
1.703.591.121.081.111.041.071.291.6841.94
1.703.590.960.971.000.930.891.061.6841.94
1.431.528.0812.559.2634.7976.2843.9123.050.02
-26.2%-5.3%27.2%19.7%35.2%59.9%-57.5%29.0%5.2%-23.3%
-10.8%-2.1%3.0%1.5%3.4%1.7%-0.7%0.6%0.2%-22.8%
------0.03---
-941 days88 days75 days98 days85 days40 days---
-244 days197 days190 days151 days177 days117 days---

A Belgian filing has no cash-flow statement. Cash flow is therefore an approximation, derived from the income statement. Investment is the acquisitions in the notes and, without them, the balance-sheet move.

Insights on NEOGEN DEVELOPMENTS

The operating result for 2019 is a loss of €66,953, larger than the loss of €23,517 in 2018. It is the lowest result since 2010.

Debt's share of the balance-sheet total falls from 60.2% to 58.8%. Equity and debt are lower.

Board & ownership

Mandates through the years

4 names
HANDS-ON FINANCE SOLUTIONS
Director
Jacobsen Management
Director
Alter Pharma NV
Director
GRNR Invest BV
Director
Earliermandate already running before its first mentionend not dated
Mandates as a list
  • HANDS-ON FINANCE SOLUTIONS
    • Director, appointed by deed of 30-03-2020, last mentioned in 2020
  • Jacobsen Management
    • Director, appointed by deed of 30-03-2020, last mentioned in 2020
  • Alter Pharma NV
    • Director, until 12-02-2020
  • GRNR Invest BV
    • Director, until 12-02-2020

See the board, name and registered office on a given date →

Control

Consolidating parent
Alter Pharma Group NV
Equity €127.0m
Loss €16.1m in 2024 (profit €43.5m in 2023)
Source: parent in own accounts 2019
consolidates
This company
NEOGEN DEVELOPMENTS
Equity €292,526
Loss €76,722 in 2019

Capital

Capital
€61,500
Source
2019 annual accounts

Owners through the years

as the annual accounts name them
NEOGEN
99%100%
100%
A.forall Group
consolidates
consolidates
A.forall Development
consolidates1%
1% until 2018
Owners as a list

Source: parent in its own accounts, lists of holdings in the owners' accounts

Capital transactions

Shareholders according to the deeds
Stated in the deed deed of 26-05-2020 ↗

Office holders in the KBO →

Network & group

Parent

Alter Pharma Group NV
0684.777.042 · equity €127.0m · loss €16.1m (2024)

Earlier ties

PI PHARMA
via HANDS-ON FINANCE SOLUTIONS, at NEOGEN DEVELOPMENTS, last mentioned in 2020 · Director · deed of 23-03-2020
founded in 2006 · negative equity (2025) · group A.forall Group
 12 FTE (2025)
Hyloris Pharmaceuticals
via Jacobsen Management, at NEOGEN DEVELOPMENTS, last mentioned in 2020 · Director · deed of 18-02-2020
founded in 2017
 turnover €3.8m (2025)
A.forall Development
via HANDS-ON FINANCE SOLUTIONS, at NEOGEN DEVELOPMENTS, last mentioned in 2020 · Director · deed of 30-03-2020
founded in 2010 · group A.forall Group
 11 FTE (2025)
MEDIGROUP
via HANDS-ON FINANCE SOLUTIONS, at NEOGEN DEVELOPMENTS, last mentioned in 2020 · Director · deed of 30-03-2020
founded in 2010 · group A.forall Group
 14 FTE (2025)
NEOGEN
via Jacobsen Management (at NEOGEN DEVELOPMENTS, last mentioned in 2020) and HANDS-ON FINANCE SOLUTIONS (at NEOGEN DEVELOPMENTS, last mentioned in 2020) · deeds of 15-02-2021 and 30-03-2020
founded in 1991 · group A.forall Group
 total assets €17.8m (2025)
IMPEXECO
via HANDS-ON FINANCE SOLUTIONS, at NEOGEN DEVELOPMENTS, last mentioned in 2020 · Director · deed of 08-04-2020
founded in 2002 · group A.forall Group
 turnover €13.3m (2025)
Show 5 more earlier ties
ECO.PHARMA.SUPPLY
via HANDS-ON FINANCE SOLUTIONS, at NEOGEN DEVELOPMENTS, last mentioned in 2020 · Director · deed of 28-04-2022
founded in 2013 · group A.forall Group
 6.8 FTE (2025)
ECOPHARMASUPPLY DISTRIBUTION
via HANDS-ON FINANCE SOLUTIONS, at NEOGEN DEVELOPMENTS, last mentioned in 2020 · Director · deed of 10-10-2022
founded in 1994 · group A.forall Group
 total assets €620,829 (2025)
STASISPORT PHARMA
via Jacobsen Management (at NEOGEN DEVELOPMENTS, last mentioned in 2020) and HANDS-ON FINANCE SOLUTIONS (at NEOGEN DEVELOPMENTS, last mentioned in 2020) · Director · deed of 30-03-2020
No longer active
 total assets €4.0m (2019)
Nordic Specialty Pharma (NSP)
via Jacobsen Management (at NEOGEN DEVELOPMENTS, last mentioned in 2020) and HANDS-ON FINANCE SOLUTIONS (at NEOGEN DEVELOPMENTS, last mentioned in 2020) · Director · deed of 30-03-2020
No longer active
 1 FTE (2019)
Neogen International
via Jacobsen Management (at NEOGEN DEVELOPMENTS, last mentioned in 2020) and HANDS-ON FINANCE SOLUTIONS (at NEOGEN DEVELOPMENTS, last mentioned in 2020) · Director · deed of 30-03-2020
No longer active
 total assets €7,212 (2019)

Acquisitions and mergers

1 transaction
Taken over by:Neogen NV
BE 0445.922.856operation treated as a merger by absorption · Gazette deed of 23-07-2020 (7 deeds)

Connections & network

Depth
A.forall Development, Shared corporate director ADA.forallDevelopmentECO.PHARMA.SUPPLY, Shared corporate director EECO.PHARMA.SU…ECOPHARMASUPPLY DISTRIBUTION, Shared corporate director EDECOPHARMASUPPLYDISTRIBUTIONHyloris Pharmaceuticals, Shared corporate director HPHylorisPharmaceuticalsIMPEXECO, Shared corporate director IIMPEXECOMEDIGROUP, Shared corporate director MMEDIGROUPNEOGEN, Shared corporate director NNEOGENNeogen International, Shared corporate director NINeogenInternationalNordic Specialty Pharma (NSP), Shared corporate director NSNordic SpecialtyPharma (NSP)PI PHARMA, Shared corporate director PPPI PHARMASTASISPORT PHARMA, Shared corporate director SPSTASISPORTPHARMANEOGEN DEVELOPMENTS NEOGENDEVELOPMENTS0808.426.110
Shared directors
This company Company Director Shareholding +N: links not shown yet Click a node to look further, drag to arrange, zoom with the mouse wheel.

Timeline

Timeline

23 events since 2008
2020
Merger: absorbed by NeogenGeneral meeting of 30-06-20202 points ▸
  • General meeting, 30-06-2020
  • Accounting effect, 01-01-2020
  • The deed holds 3 more points.

Open the deed in the Belgian Official Gazette

Annual accounts 2019 filed PDFabbreviated format · 17 days before the deadline
Merger proposal: to be absorbed by Neogen NVPermanent representative: Julie Delforge · Neogen NV holds all the shares · Alter Pharma NV holds all the shares5 points ▸
  • Neogen NV holds all the shares, mentioned twice in the deed
  • Alter Pharma NV holds all the shares, mentioned twice in the deed
  • Capital, €5,255,197.80, 9,807 shares
  • Accounting effect, 01-01-2020
  • Permanent representative, Julie Delforge
  • The deed holds 12 more points.

Open the deed in the Belgian Official Gazette

2 directors appointed, 2 resignationsResignations: GRNR Invest BV and Alter Pharma NV · Permanent representatives: Thomas Jacobsen, Pieter Van Rompay and Ivo Peeters · Appointments: Jacobsen Management BV and HFS BV · General meeting of 12-02-20209 points ▸
  • General meeting, 12-02-2020
  • Director resignation, GRNR Invest BV
  • Director resignation, Alter Pharma NV
  • Permanent representative, Thomas Jacobsen, mentioned twice in the deed
  • Permanent representative, Pieter Van Rompay
  • Director appointment, Jacobsen Management BV
  • Director appointment, HFS BV
  • Permanent representative, Ivo Peeters
  • Board meeting, 12-02-2020
  • The deed holds 2 more points.

Open the deed in the Belgian Official Gazette

2019
Weakest financial year net -€76,722 The net result drops to -€76,722, the lowest from 2010 to 2019.
Annual accounts 2018 filed PDFfull format · 22 days before the deadline
2018
Liquidity more than triples current ratio 3.59 The current ratio rises from 1.12 to 3.59. Short-term debt falls from €2.5m to €258,824.
Annual accounts 2018 filed PDFfull format · 5 days before the deadline
2017
Annual accounts 2017 filed PDFfull format · 8 days late
Highest result from 2010 to 2019 net €84,367 ▲89.7% The net result of €84,367 is the highest of those years.
2016
Annual accounts 2016 filed PDFfull format · 6 days before the deadline
Equity above €200,000 equity €225,566 ▲24.6% After 3 profitable years in a row, equity reaches €225,566.
2015
Annual accounts 2015 filed PDFfull format · 12 days before the deadline
Equity above €150,000 equity €181,102 ▲54.4% After 2 profitable years in a row, equity reaches €181,102.
2014
Annual accounts 2014 filed PDFfull format · 3 days before the deadline
Back to profit net €70,305 The net result is €70,305, after one loss-making year.
Equity above €100,000 equity €117,325 ▲150% Equity rises from €47,020 to €117,325.
2013
Annual accounts 2013 filed PDFfull format · on the deadline day
2012
Annual accounts 2012 filed PDFabbreviated format · 6 days before the deadline
2011
Annual accounts 2011 filed PDFabbreviated format · 28 days late
Back to profit net €2,728 The net result is €2,728, after one loss-making year.
2010
Annual accounts 2010 filed PDFabbreviated format · 34 days before the deadline
2008
Incorporation PDF12 publications in the Belgian Official Gazette, the last on 23-07-2020

Financial milestones sit on the financial year-end date, not the filing date.

Sources: Publications in the Belgian Official GazetteFilings with the National Bank

History

NEOGEN DEVELOPMENTS has filed 11 sets of annual accounts, the latest for financial year 2019.1 In 2020 the company was absorbed by merger into Neogen NV.2

  1. 1National Bank, annual accounts 2019
  2. 2Belgian Official Gazette, 23-07-2020

Company details

Purpose according to the articles of association

PurposeThe purpose describes the activities the company may carry out under its articles.
“Alle roerende,onroerende,financiële,industriële,commerciële of burgerrechtelijke verrichtingen binnen de perken van haar maatschappelijk…”
2 activities
  1. Alle roerende,onroerende,financiële,industriële,commerciële of burgerrechtelijke verrichtingen binnen de perken van haar maatschappelijk doel,zowel in België als in het buitenland
  2. De aankoop,de verkoop,de invoer-uitvoer,de levering,de vertegenwoordiging,de distributie en de commercialisering van alle farmaceutische producten

Articles of association, deed of 26-05-2020 (in Dutch)

Inactive

Absorbed by Neogen NV in July 2020

NEOGEN DEVELOPMENTS is no longer in the KBO register. Neogen NV took it over in a merger by absorption, published in the Belgian Official Gazette on 23 July 2020.

Status
Inactive
Reason
Merger by absorption"operation treated as a merger by absorption", Belgian Official Gazette, 23 July 2020 · deed
Absorbed by
Neogen NV · 0445.922.856
Last annual accounts
financial year to 31 December 2019
Last registered office
Square Marie Curie 50, 1070 Anderlechtas published on 23 July 2020
Legal form
Public limited company
First annual accounts
financial year 2010
Official KBO record

We would like to set cookies. That happens only with your consent. What we measure